Trial reportCirculation research2017
Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study).
Registry-linked trialAbstract readClinical Trial, Phase IIComparative StudyRandomized Controlled Trial
In one paragraph
Trial report in Circulation research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02013674 (A Phase II, Randomized, Blinded, Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Human Mesenchymal Stem Cells), which is not on this map. Cited by 115 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 5 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II, Randomized, Blinded, Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Human Mesenchymal Stem Cells (hMSCs) (20 Million or 100 Million Total MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction.
Who cites it
115 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Efficacy and Safety of Intracoronary Mesenchymal Stem Cell Administration in ST-Segment Elevation Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials.Clinical and translational science · 2026Pooled it
- Stem cell therapy for patients with acute myocardial infarction: a systematic review of clinical trials.Stem cell research & therapy · 2025Pooled it
- Mid- to long-term efficacy and safety of stem cell therapy for acute myocardial infarction: a systematic review and meta-analysis.Stem cell research & therapy · 2024Pooled it
- Dose-response relationship of MSCs as living Bio-drugs in HFrEF patients: a systematic review and meta-analysis of RCTs.Stem cell research & therapy · 2024Pooled it
- Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis.Stem cell research & therapy · 2019Pooled it
- Plasma Small Extracellular Vesicle Cardiac miRNA Expression in Patients with Ischemic Heart Failure, Randomized to Percutaneous Intramyocardial Treatment of Adipose Derived Stem Cells or Placebo: Subanalysis of the SCIENCE Study.International journal of molecular sciences · 2023Trial
- Effect of cardiosphere-derived cells on segmental myocardial function after myocardial infarction: ALLSTAR randomised clinical trial.Open heart · 2021Trial
- Bone marrow mesenchymal stem cells transfer in patients with ST-segment elevation myocardial infarction: single-blind, multicenter, randomized controlled trial.Stem cell research & therapy · 2021Trial
- Next-Generation Bone Marrow Cell Therapies for Cardiac Repair: Integrating Gene Therapy and Bioengineering to Enhance Therapeutic Potency.Journal of cardiovascular translational research · 2026Review
- Mesenchymal Stromal Cell Therapy in Cardiovascular Disease: Reconsidering Clinical Inconsistency Through the Mechanism-Endpoint Relationship.Reviews in cardiovascular medicine · 2026Review
- A HEART-WISE: Allogeneic Wharton's Jelly-derived Mesenchymal Stromal Cells' Intracoronary Transplantation in Pediatric Patients with Dilated Cardiomyopathy: The First Case Reports.BMC cardiovascular disorders · 2026Article
- Article
- Emerging Smart and Adaptive Hydrogels for Next-Generation Tissue Engineering.Bioengineering (Basel, Switzerland) · 2025Review
- Cell Surface Markers of Mesenchymal Stem Cells: Current Knowledge and Advances in Characterization Technologies.Life (Basel, Switzerland) · 2025Review
- A comprehensive review of clinical trials and Progress in stem cell therapies for advanced heart failure.Regenerative therapy · 2025Review
- Current status and new horizons in stem cell therapy in cardiovascular regenerative medicine (CaVaReM): an update.European journal of medical research · 2025Review
- Stem Cell Therapy in Ischemic Heart Failure.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Review
- Therapeutic effect of mesenchymal stem cells and their derived exosomes in diseases.Molecular biomedicine · 2025Review
- Navigating mesenchymal stem cells doses and delivery routes in heart disease trials: A comprehensive overview.Regenerative therapy · 2025Review
- An overview on cardiac regeneration revolution: exploring the promise of stem cell therapies.Molecular biology reports · 2025Review
55 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
31 authors.
Victoria FloreaFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Angela C RiegerFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Darcy L DiFedeFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Jill El-KhorazatyFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Makoto NatsumedaFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Monisha N BanerjeeFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Bryon A TompkinsFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Aisha KhanFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Ivonne H SchulmanFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Ana Marie LandinFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Muzammil MushtaqFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Samuel GolpanianFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Maureen H LoweryFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
John J ByrnesFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Robert C HendelFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Mauricio G CohenFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Krystalenia ValasakiFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Marietsy V PujolFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Eduard GhersinFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Roberto MikiFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Cindy DelgadoFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Fouad AbuzeidFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Mayra Vidro-CasianoFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Russell G SaltzmanFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Daniel DaFonsecaFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Lina V CaceresFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Kevin N RamdasFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Adam MendizabalFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Alan W HeldmanFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Raul D MitraniFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.).
Joshua M HareFrom the Interdisciplinary Stem Cell Institute (V.F., A.C.R., M.N., M.N.B., B.A.T., A.K., I.H.S., A.M.L., S.G., K.V., M.V.P., C.D., F.A., M.V.-C., R.G.S., D.D., L.V.C., K.N.R., A.W.H., R.D.M., J.M.H.), Department of Surgery (M.N.B., B.A.T., S.G.), Katz Family Division of Nephrology and Hypertension (I.H.S.), Department of Medicine (M.M., M.H.L., J.J.B., R.C.H., M.G.C., R.M., R.D.M., J.M.H.), and Department of Radiology (E.G.), University of Miami Miller School of Medicine, FL; The Emmes Corporation, Rockville, MD (J.E.-K., A.M.); and Longeveron LLC, Miami, FL (D.L.D.). jhare@med.miami.edu.
Funding
ZINC AND CA EDTA THERAPY OF PLUMBISMM01RR000052 · NCRR · JOHNS HOPKINS UNIVERSITY · PI VINING, EILEEN PATRICE · 1985 to 2007
$37.3MCellular Cardiomyoplasty for Chronic Heart FailureR01HL084275 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2007 to 2016
$3.8MMesenchymal stem cell therapy for endothelial dysfunction in diabetesR01HL134558 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2016 to 2020
$3.2MStem Cells for Dilated CardiomyopathyR01HL110737 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2011 to 2015
$3.2MAging impairs stem-cell mediated myocardial repairR01AG025017 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2004 to 2008
$1.5MNCRR NIH HHS M01 RR000052NHLBI NIH HHS R01 HL084275NHLBI NIH HHS R01 HL110737NHLBI NIH HHS R01 HL134558NIA NIH HHS R01 AG025017
Abstract
rationaleCell dose and concentration play crucial roles in phenotypic responses to cell-based therapy for heart failure.
objectiveTo compare the safety and efficacy of 2 doses of allogeneic bone marrow-derived human mesenchymal stem cells identically delivered in patients with ischemic cardiomyopathy. METHODS AND
resultsThirty patients with ischemic cardiomyopathy received in a blinded manner either 20 million (n=15) or 100 million (n=15) allogeneic human mesenchymal stem cells via transendocardial injection (0.5 cc per injection × 10 injections per patient). Patients were followed for 12 months for safety and efficacy end points. There were no treatment-emergent serious adverse events at 30 days or treatment-related serious adverse events at 12 months. The Major Adverse Cardiac Event rate was 20.0% (95% confidence interval [CI], 6.9% to 50.0%) in 20 million and 13.3% (95% CI, 3.5% to 43.6%) in 100 million (
conclusionsAlthough both cell doses reduced scar size, only the 100 million dose increased ejection fraction. This study highlights the crucial role of cell dose in the responses to cell therapy. Determining optimal dose and delivery is essential to advance the field, decipher mechanism(s) of action and enhance planning of pivotal Phase III trials. CLINICAL
trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT02013674.
Indexed as
AdultAgedAged, 80 and overBiomarkersCardiomyopathiesFemaleFloridaHealth StatusHumansMaleMesenchymal Stem Cell TransplantationMiddle AgedMyocardial InfarctionMyocardiumNatriuretic Peptide, BrainPeptide FragmentsBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)bone marrowcell-based therapyheart failurehospitalizationstem cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02013674ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.